Results 221 to 230 of about 18,416,887 (403)

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

Molecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande, Marcela de Oliveira Silva, Mariana Bisarro dos Reis, Rodrigo de Oliveira Cavagna, Luciane Sussuchi, Icaro Alves Pinto, Natalia Zampieri Pontes, Rodrigo Sampaio Chiarantano, Flavio Augusto Ferreira da Silva, Pedro de Marchi, Letícia Ferro Leal, Rui M. Reis   +11 more
wiley   +1 more source

Cancer Cell Dormancy and Chemotherapy Resistance. [PDF]

J Cancer
Hu J, Zhou W, Zhao Y, Li P, Zhao Z, Wang W, Wang W, Wang Y.   +7 more
europepmc   +1 more source

The p38 MAPK-regulated PKD1/CREB/Bcl-2 pathway contributes to selenite-induced colorectal cancer cell apoptosis in vitro and in vivo

, 2014
Kaiyan Hui, Yang Yang, Kejian Shi, Hui Luo, Jing Duan, Jiajia An, Pa Wu, Yali Ci, Lei Shi, Caimin Xu   +9 more
openalex   +1 more source

Evaluation of the 3‐minute chair rise test as part of preoperative evaluation for patients with non‐small cell lung cancer

, 2020
Mathilde Azzi, David Debeaumont, Tristan Bonnevie, B. Aguilaniu, Damiano Cerasuolo, Fairuz Boujibar, A. Cuvelier, Francis‐Edouard Gravier   +7 more
openalex   +1 more source

Aggressive prostate cancer is associated with pericyte dysfunction

Molecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero, Ane Martinez‐Larrinaga, Joaquim Grego‐Bessa, Saioa Garcia‐Longarte, Hielke van Splunder, Ianire Astobiza, Amaia Ercilla, Laura Bozal‐Basterra, Isabel Mendizabal, Pilar Villacampa, Arkaitz Carracedo, Mariona Graupera   +11 more
wiley   +1 more source

Advances in Colorectal Cancer Cell Biology and Clonal Evolution. [PDF]

Int J Mol Sci
Toghey S, Harvey-Jones EJ, Towler JD, Hafkamp CJH, Chong IY.   +4 more
europepmc   +1 more source

Tumor PD-L1 status and CD8+ tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal cancer

, 2017
Astrid De Meulenaere, Tijl Vermassen, Sandrine Aspeslagh, Philippe Deron, Fréderic Duprez, Debby Laukens, Jo Van Dorpe, Liesbeth Ferdinande, Sylvie Rottey   +8 more
openalex   +2 more sources

KRASQ61H Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Non–Small Cell Lung Cancer [PDF]

, 2020
Zhi-Wei Zhou, Chiara Ambrogio, Asim K. Bera, Qing Li, Xing-Xiao Li, Lianbo Li, Jieun Son, Sudershan Reddy Gondi, Jiaqi Li, Emily Campbell, Hua Jin, Jeffrey J. Okoro, Cheng‐Xiong Xu, Pasi A. Jänne, Kenneth D. Westover   +14 more
openalex   +1 more source

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

Molecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard, Cristina Mitric, Melanie Care, Tracy L. Stockley, Raymond H. Kim, Jeanna McCuaig, Blaise Clarke, Laura Ranich, Clare Sheen, Sarah E. Ferguson, Liat Hogen, Taymaa May, Marcus Q. Bernardini   +12 more
wiley   +1 more source

Focal Adhesion and Cancer Cell Cycle-Associated Resistance. [PDF]

ACS Omega
Ruksha TG, Palkina NV, Lapkina EZ, Liu K.   +3 more
europepmc   +1 more source